Efficacy of Selective Laser Trabeculoplasty in Patients on Systemic Immunosuppressive Therapy

被引:1
作者
Kaplan, Tyler M. [1 ]
Hammer, Jon D. [1 ]
Kohli, Darrel [1 ]
Pacheco, Johann M. [1 ]
Hodge, David O. [2 ]
Khanna, Cheryl L. [1 ]
Sit, Arthur J. [1 ]
Roddy, Gavin W. [1 ]
机构
[1] Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Quantitat Hlth Sci, Jacksonville, FL USA
关键词
glaucoma; ocular hypertension; selective laser trabeculoplasty; immunosuppression; immunosuppressive therapy; GLAUCOMA; ND; INCREASE; PILOT; CELLS; EYE;
D O I
10.1097/IJG.0000000000002259
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Precis:When comparing patients on systemic immunosuppressive therapy to those without, there was no difference in intraocular pressure (IOP) early after SLT; however, at 1 year following SLT, IOP was higher in the immunosuppression group compared with controls.Purpose:To determine whether patients taking systemic immunosuppressive medications have a different IOP-lowering response to selective laser trabeculoplasty (SLT) compared with a control group of patients.Methods:All patients who underwent SLT at Mayo Clinic 2017-2021 were identified. Patients on systemic immunosuppressive medications at the time of SLT were compared with control patients not receiving systemic immunosuppressive medications. The primary endpoints of this study were the percentage IOP reduction at 1 to 2, 3 to 6, and 12 months. Additional analyses included the percentage of patients who did not require additional therapy at each time point.Results:There were 108 eyes of 72 patients that underwent SLT in the immunosuppressed group and 1997 eyes of 1417 patients in the control group. There was no significant difference in age-adjusted change in IOP between groups at the first postoperative visit 1 to 2 months following SLT (-18.8 & PLUSMN;20.7% vs. -16.0 & PLUSMN;16.5%, P=0.256) or 3-6 months following SLT (-15.2 & PLUSMN;21.6% vs. -18.3 & PLUSMN;23.2%, P=0.062). However, at 12 months following SLT, the IOP reduction in the immunosuppressive therapy group was significantly less compared with the control group (-15.1 & PLUSMN;21.2% vs. -20.3 & PLUSMN;22.9%, P=0.045). There was no difference between groups in the number of additional treatments during the study intervals.Conclusion:Patients in the systemic immunosuppressive therapy group showed equivalent early IOP-lowering after SLT compared with a control group, but the treatment response was diminished at 1 year. Further studies investigating IOP regulation after SLT in immunosuppressed patients are needed.
引用
收藏
页码:762 / 768
页数:7
相关论文
共 28 条
  • [1] THE NORMAL-DISTRIBUTION
    ALTMAN, DG
    BLAND, JM
    [J]. BRITISH MEDICAL JOURNAL, 1995, 310 (6975) : 298 - 298
  • [2] A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells
    Alvarado, JA
    Alvarado, RG
    Yeh, RF
    Franse-Carman, L
    Marcellino, GR
    Brownstein, MJ
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (11) : 1500 - 1505
  • [3] Similar Effects of Selective Laser Trabeculoplasty and Prostaglandin Analogs on the Permeability of Cultured Schlemm Canal Cells
    Alvarado, Jorge A.
    Iguchi, Rumiko
    Martinez, Juan
    Trivedi, Sheetal
    Shifera, Amde Selassie
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (02) : 254 - 264
  • [4] Predictive factors of success in selective laser trabeculoplasty (SLT) treatment
    Ayala, Marcelo
    Chen, Enping
    [J]. CLINICAL OPHTHALMOLOGY, 2011, 5 : 573 - 576
  • [5] II. Selective Laser Trabeculoplasty: A Better Alternative
    Damji, Karim E.
    [J]. SURVEY OF OPHTHALMOLOGY, 2008, 53 (06) : 646 - 651
  • [6] Multiple Systemic Vascular Risk Factors Are Associated With Low-Tension Glaucoma
    Funk, Robert O.
    Hodge, David O.
    Kohli, Darrell
    Roddy, Gavin W.
    [J]. JOURNAL OF GLAUCOMA, 2022, 31 (01) : 15 - 22
  • [7] Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT
    Gazzard, Gus
    Konstantakopoulou, Evgenia
    Garway-Heath, David
    Garg, Anurag
    Vickerstaff, Victoria
    Hunter, Rachael
    Ambler, Gareth
    Bunce, Catey
    Wormald, Richard
    Nathwani, Neil
    Barton, Keith
    Rubin, Gary
    Morris, Stephen
    Buszewicz, Marta
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2019, 23 (31) : 1 - +
  • [8] SALT Trial: Steroids after Laser Trabeculoplasty Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy
    Groth, Sylvia L.
    Albeiruti, Eiyass
    Nunez, Mariana
    Fajardo, Roman
    Sharpsten, Lucie
    Loewen, Nils
    Schuman, Joel S.
    Goldberg, Jeffrey L.
    [J]. OPHTHALMOLOGY, 2019, 126 (11) : 1511 - 1516
  • [9] An Experimental Steroid Responsive Model of Ocular Inflammation in Rabbits Using an SLT Frequency Doubled Q Switched Nd:YAG Laser
    Gulati, Vikas
    Pahuja, Sandhya
    Fan, Shan
    Toris, Carol B.
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (07) : 663 - 669
  • [10] Guo K L, 1995, J Glaucoma, V4, P268